During the past decade, Ottawa Hospital and Cancer Center-General Campus conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 26 clinical trials were completed, i.e. on average, 113% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 15 clinical trials were completed. i.e. 750% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ottawa Hospital and Cancer Center-General Campus" #1 sponsor was "National Cancer Institute (NCI)" with 19 trials, followed by "NRG Oncology" with 7 trials sponsored, "Alliance for Clinical Trials in Oncology" with 6 trials sponsored, "SWOG Cancer Research Network" with 4 trials sponsored and "Hoffmann-La Roche" with 4 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ottawa Hospital and Cancer Center-General Campus" #1 collaborator was "National Cancer Institute (NCI)" with 20 trials as a collaborator, "Canadian Cancer Trials Group" with 5 trials as a collaborator, "NRG Oncology" with 4 trials as a collaborator, "SWOG Cancer Research Network" with 4 trials as a collaborator and "Cancer and Leukemia Group B" with 3 trials as a collaborator. Other collaborators include 13 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "Ottawa Hospital and Cancer Center-General Campus" are "Recurrent Squamous Cell Lung Carcinoma" (4 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (3 trials), "Breast Cancer" (2 trials), "Endometrial Serous Adenocarcinoma" (2 trials) and "Ovarian Seromucinous Carcinoma" (2 trials). Many other conditions were trialed in "Ottawa Hospital and Cancer Center-General Campus" in a lesser frequency.

Most popular intervention types in "Ottawa Hospital and Cancer Center-General Campus" are "Drug" (31 trials), "Other" (29 trials), "Radiation" (13 trials), "Biological" (12 trials) and "Procedure" (9 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (20 trials), "Quality-of-Life Assessment" (11 trials), "Pharmacological Study" (6 trials), "Ipilimumab" (5 trials) and "Placebo" (5 trials). Other intervention names were less common.

The vast majority of trials in "Ottawa Hospital and Cancer Center-General Campus" are 31 trials for "All" genders, 11 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Ottawa Hospital and Cancer Center-General Campus". undefined are not yet recruiting, 4 are recruiting, 23 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Ottawa Hospital and Cancer Center-General Campus, 2 suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Ottawa Hospital and Cancer Center-General Campus, 0 "Phase 1" clinical trials were conducted, 18 "Phase 2" clinical trials and 30 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".